PF-3882845 manufacturers
- PF-3882845
-
- $472.00
-
2026-07-27
- CAS:1023650-66-9
- Purity: 99.63%
- Supply Ability: 10g
|
| | PF-3882845 Basic information |
| Product Name: | PF-3882845 | | Synonyms: | (3S,3aR)-2-(3-Chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid;PF-3882845;2H-Benz[g]indazole-7-carboxylic acid, 2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-, (3S,3aR)-;PF-03882845 >=98% (HPLC);(3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydrobenzo[g]indazole-7-carboxylic acid;PF3882845,PF 3882845;(3S,3aR)-2-(3-Chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benz[g]indazole-7-carboxylic acid;PF-03882845 | | CAS: | 1023650-66-9 | | MF: | C24H22ClN3O2 | | MW: | 419.9 | | EINECS: | | | Product Categories: | | | Mol File: | 1023650-66-9.mol |  |
| | PF-3882845 Chemical Properties |
| storage temp. | room temp | | solubility | DMSO: soluble10mg/mL, clear | | form | powder | | color | white to beige | | InChIKey | XNULRSOGWPFPBL-REWPJTCUSA-N | | SMILES | OC(C1=CC2=C(C=C1)C3=NN(C4=CC=C(C#N)C(Cl)=C4)[C@@H](C5CCCC5)[C@@]3([H])CC2)=O |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36/37/39 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | PF-3882845 Usage And Synthesis |
| Uses | PF-3882845 is a remarkably high affinity selective and orally efficacious mineralocorticoid receptor (MR binding IC50=2.7 nM) antagonist for hypertension and nephropathy. PF-3882845 also binds to progesterone receptor (PR) with the binding IC50 of 310 nM[1]. | | Biological Activity | PF-03882845 is a potent non-steroidal mineralocorticoid antagonist with and IC50 of 0.755 nM, compared to eplerenone with an IC50 of 109 nM. PF-03882845 was tested in a r at model for renal protection against aldosterone-mediated renal disease, and found to be more potent than eplerenone in suppressing the urinary albumin to creatinine ratio (UACR), a measure of renal fibrosis. The therapeutic index, calculated as the ratio of the EC50 for increasing serum K+ to the EC50 for UACR lowering, was 83.8 for PF-03882845 and 1.47 for eplerenone. | | in vivo | PF-3882845 reduces blood pressure, decreases urinary albumin, and protects kidney in Dahl SS rat[1].
PF-3882845 exhibits moderate oral bioavailability (F 86%) following oral administration (2 mg/kg) in male Sprague-Dawley rats[1].
PF-3882845 exhibits terminal elimination half-lives (T1/2 1.7 h) due to high plasma clearance (CL 9.8 mL/min/kg) combined with large volumes of distribution (Vdss 1.4 mL/kg respectively) following intravenous administration (2 mg/kg) in male Sprague-Dawley rats[1].
| Animal Model: | Male Dahl salt sensitive (SS) rats[1] | | Dosage: | 10, 40, and 100 mg/kg | | Administration: | Orally via gavage; twice a day; for 21 days | | Result: | Significant blood pressure reduction was observed with 10 mg/kg. Most noticeably, rats dosed at 40 and 100 mg/kg had negligible increase in blood pressure over 21 days in the presence of high salt. |
| | References | [1] Meyers MJ, et al. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem. 2010 Aug 26;53(16):5979-6002. DOI:10.1021/jm100505n |
| | PF-3882845 Preparation Products And Raw materials |
|